🇺🇸 FDA
Drug

adagrasib

Brand: KRAZATI

approved

Quick answer

adagrasib (KRAZATI), is a pharmaceutical active ingredient, with approved status in the US.

Key facts

INN
adagrasib
Brand
KRAZATI
Route
ORAL
Formulation
TABLET

Related patents

patent

US 12383503

Adagrasib solid pharmaceutical compositions

Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

Related news

FDA Approval Adagrasib: Accelerated OK for KRAS G12C NSCLC Treatment
Newsnon-small cell lung cancerApr 20, 2026

FDA Approval Adagrasib: Accelerated OK for KRAS G12C NSCLC Treatment

Adagrasib receives FDA accelerated approval for KRAS G12C NSCLC, marking a significant advancement in targeted lung cancer treatment options.

Dr. Sarah Mitchell

Frequently asked questions

What is adagrasib?

adagrasib (KRAZATI), is a pharmaceutical active ingredient, with approved status in the US.

What is the brand name for adagrasib?

KRAZATI is a marketed brand name for adagrasib. Check FDA Drugs@FDA for the current US label holder.